Press release from Companies
Publicerat: 2018-04-10 09:15:41
The drug Prednisolon EQL Pharma has now been approved for sale by the Swedish Medicines Agency.
Prednisolone EQL Pharma is used in the state where one needs to suppress the body's reaction such as the inflammatory response in rheumatoid arthritis (RA). Other examples mentioned include connective tissue disease (SLE), vessel wall inflammation, connective tissue changes, asthma, colitis colitis, certain blood disorders, severe allergic conditions and tumor therapy. In the Nordic region, the Swedish market is the largest with about 25 million SEK in annual sales. There are only a few competitors in the Nordic region in accordance with EQL Pharmas long-term strategy. The product is expected to be launched in the second half of 2018.